Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Literature Report

Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.

Cancer research | 2023

Malignant gliomas such as glioblastoma are highly heterogeneous with distinct cells of origin and varied genetic alterations. It remains elusive whether the specific states of neural cell lineages are differentially susceptible to distinct genetic alterations during malignant transformation. Here, an analysis of The Cancer Genome Atlas databases revealed that comutations of PTEN and TP53 are most significantly enriched in human high-grade gliomas. Therefore, we selectively ablated Pten and Trp53 in different progenitors to determine which cell lineage states are susceptible to malignant transformation. Mice with PTEN/p53 ablation mediated by multilineage-expressing human GFAP (hGFAP) promoter-driven Cre developed glioma but with incomplete penetrance and long latency. Unexpectedly, ablation of Pten and Trp53 in Nestin+ neural stem cells (NSC) or Pdgfra+/NG2+ committed oligodendrocyte precursor cells (OPC), two major cells of origin in glioma, did not induce glioma formation in mice. Strikingly, mice lacking Pten and Trp53 in Olig1+/Olig2+ intermediate precursors (pri-OPC) prior to the committed OPCs developed high-grade gliomas with 100% penetrance and short latency. The resulting tumors exhibited distinct tumor phenotypes and drug sensitivities from NSC- or OPC-derived glioma subtypes. Integrated transcriptomic and epigenomic analyses revealed that PTEN/p53-loss induced activation of oncogenic pathways, including HIPPO-YAP and PI3K signaling, to promote malignant transformation. Targeting the core regulatory circuitries YAP and PI3K signaling effectively inhibited tumor cell growth. Thus, our multicell state in vivo mutagenesis analyses suggests that transit-amplifying states of Olig1/2 intermediate lineage precursors are predisposed to PTEN/p53-loss-induced transformation and gliomagenesis, pointing to subtype-specific treatment strategies for gliomas with distinct genetic alterations.

Pubmed ID: 36634201 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.

Mouse Anti-Actin Monoclonal Antibody, Unconjugated, Clone AC-40 (antibody)

RRID:AB_476730

This monoclonal targets Actin

View all literature mentions

EGF Receptor (D38B1) XP Rabbit mAb (antibody)

RRID:AB_2246311

This monoclonal targets EGF Receptor

View all literature mentions

HER3/ErbB3 (D22C5) XP® Rabbit mAb (antibody)

RRID:AB_2721919

This monoclonal targets HER3/ErbB3

View all literature mentions

Sox9 (D8G8H) Rabbit mAb #82630 (antibody)

RRID:AB_2665492

This monoclonal targets Sox9

View all literature mentions

Anti-SOX10 antibody [EPR4007-104] (antibody)

RRID:AB_2721184

This monoclonal targets SOX10

View all literature mentions

YAP/TAZ (D24E4) Rabbit mAb (antibody)

RRID:AB_10950494

This monoclonal targets Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp362 of human TAZ protein

View all literature mentions